Research programme: nutlin tumour suppressors - RocheAlternative Names: Nutlin-1; Nutlin-2; Nutlin-3; Nutlin-3a; Nutlins
Latest Information Update: 14 Aug 2014
At a glance
- Originator Roche
- Class Imidazolines; Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer